For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Chemical/ Small Molecule corresponding to N6-methyladenosine (m6A) conjugated to keyhole limpet haemocyanin.
N6-methyladenosine (m6A) is a post-transcriptional modification of RNA. m6A modification has been identified in all classes of RNA (rRNA, tRNA and mRNA) and is catalysed by an evolutionary conserved multi-subunit enzyme, methyltransferase like 3 (METTL3). Cellular and viral RNA has been known to be methylated for decades. Recent studies have found that mRNA is predominately m6A modified at stop codons and long internal exons, which are conserved between mouse and human. Emerging evidence suggests m6A plays an important role in regulating gene expression, alternative splicing patterns, downstream signalling (p53) as well as apoptosis.
The regulation of m6A modifications in mRNA has been linked to disease, where fat mass and obesity-associated (FTO) has been has been reported to be a obesity risk gene. FTO is a m6A demethylase and polymorphisms that result in increased FTO expression are associated with increased body mass and risk of obesity.
Our Abpromise guarantee covers the use of ab151230 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Nucleotide Array||Use a concentration of 2 µg/ml.|
All batches of ab151230 are tested in Nucleotide Array against N6-methyladenosine (m6A) and unmodified adenosine. Six dilutions of each oligomer are printed on to the Array in triplicate and results are averaged before being plotted on to a graph. Results show strong binding to N6-methyladenosine, indicating that this antibody specifically recognises adenosine methylated at position N6.
2Ome-m6A - N6-methyladenosine
2Ome-m6A_unmod - unmodified adenosine
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"